Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jun 23;59(12):5650-60.
doi: 10.1021/acs.jmedchem.6b00389. Epub 2016 Jun 7.

Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development

James F Blake  1 , Michael Burkard  1 , Jocelyn Chan  2 , Huifen Chen  2 , Kang-Jye Chou  2 , Dolores Diaz  2 , Danette A Dudley  2 , John J Gaudino  1 , Stephen E Gould  2 , Jonas Grina  1 , Thomas Hunsaker  2 , Lichuan Liu  2 , Matthew Martinson  1 , David Moreno  1 , Lars Mueller  2 , Christine Orr  2 , Patricia Pacheco  2 , Ann Qin  2 , Kevin Rasor  1 , Li Ren  1 , Kirk Robarge  2 , Sheerin Shahidi-Latham  2 , Jeffrey Stults  2 , Francis Sullivan  1 , Weiru Wang  2 , Jianping Yin  2 , Aihe Zhou  2 , Marcia Belvin  2 , Mark Merchant  2 , John Moffat  2 , Jacob B Schwarz  2
Affiliations

Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development

James F Blake et al. J Med Chem. .

Abstract

The extracellular signal-regulated kinases ERK1/2 represent an essential node within the RAS/RAF/MEK/ERK signaling cascade that is commonly activated by oncogenic mutations in BRAF or RAS or by upstream oncogenic signaling. While targeting upstream nodes with RAF and MEK inhibitors has proven effective clinically, resistance frequently develops through reactivation of the pathway. Simultaneous targeting of multiple nodes in the pathway, such as MEK and ERK, offers the prospect of enhanced efficacy as well as reduced potential for acquired resistance. Described herein is the discovery and characterization of GDC-0994 (22), an orally bioavailable small molecule inhibitor selective for ERK kinase activity.

PubMed Disclaimer

MeSH terms